Hidradenitis Suppurativa Therapeutics Market Size was nearly USD ~1,400 million in the 7MM in 2023, estimated DelveInsight

DelveInsight's "Hidradenitis Suppurativa Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of hidradenitis suppurativa, historical and forecasted epidemiology as well as the hidradenitis suppurativa market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Hidradenitis Suppurativa Market with DelveInsight's In-Depth Report @ Hidradenitis Suppurativa Market Size [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hidradenitis Suppurativa Market Report

* In December 2024:- UCB Biopharma SRL- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa. The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).
* In 2023, the total Hidradenitis Suppurativa Prevalenct Cases in the 7MM were nearly 6.2 million. These cases are anticipated to increase by 2034.
* In the 7MM, the US accounted for the highest number of Hidradenitis Suppurativa Diagnosed Prevalent Cases with nearly 877,600 in 2023.
* Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa Diagnosed Prevalent Cases whereas Spain occupied the bottom of the ladder.
* In the US, EU4 and the UK, hidradenitis suppurativa was seen to be slightly more common in females (~75%) than males (~25%). Conversely, in Japan, males represent nearly 70% of the total cases, while females account for around 30%.
* The age-specific data revealed that hidradenitis suppurativa was most prevalent in the age group of 30-39 years, which was nearly 26% of the total diagnosed cases of hidradenitis suppurativa in the US.
* Among all, Hurley Stage I was observed to be most prevalent, with approximately 480,000 cases in 2023 in the US.
* The leading Hidradenitis Suppurativa Companies such as Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics, Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, Aristea Therapeutics , and others.
* Promising Hidradenitis Suppurativa Pipeline Therapies such as IFX-1, Cosentyx /Secukinumab, Avacopan, Bimekizumab, Bermekimab, Zunsemetinib (ATI-450 ), and others.

Stay ahead in the Hidradenitis Suppurativa Therapeutics Market with DelveInsight's Strategic Report @ Hidradenitis Suppurativa Market Outlook [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Hidradenitis Suppurativa Epidemiology

* Total Hidradenitis Suppurativa Prevalent Cases
* Total Hidradenitis Suppurativa Diagnosed Prevalent Cases
* Hidradenitis Suppurativa Gender-Specific Prevalent Cases
* Hidradenitis Suppurativa Age-specific Prevalent Cases
* Hidradenitis Suppurativa Stage-specific Prevalent cases
* Hidradenitis Suppurativa Treated Prevalent Cases

Download the report to understand which factors are driving Hidradenitis Suppurativa Epidemiology trends @ Hidradenitis Suppurativa Prevalence [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Hidradenitis Suppurativa Marketed Drugs

* HUMIRA (adalimumab): AbbVie/Eisai

HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). In September 2015, the US FDA approved HUMIRA for the treatment of moderate-to-severe hidradenitis suppurativa in adults, and later in October 2018, for patients =12 years of age as well. The recommended dose of HUMIRA for adult patients with hidradenitis suppurativa is an initial dose of 160 mg (given in 1 day or split over 2 consecutive days), followed by 80 mg 2 weeks later. In Europe and Japan, HUMIRA biosimilars were launched in 2018 and 2021. In September 2016, AMJEVITA became the first FDA-approved biosimilar for HUMIRA. Then, in January 2023, it became the first HUMIRA biosimilar to be launched in the US.

* BIMZELX (Bimekizumab): UCB Biopharma

Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. In April 2024, UCB announced that the European Commission granted marketing authorization for BIMZELX for the treatment of active moderate-to-severe hidradenitis suppurativa in adults with an inadequate response to conventional systemic hidradenitis suppurativa therapy. The approval follows a positive opinion issued in March 2024 by the Committee for Medicinal Products for Human Use of the EMA. In addition, in April 2024, the US FDA accepted for review the sBLA for BIMZELX for the treatment of adults with moderate-to-severe hidradenitis suppurativa. The drug has also been filed with PMDA in Japan for treating hidradenitis suppurativa.

Hidradenitis Suppurativa Emerging Drugs

* Povorcitinib (INCB054707): Incyte Corporation

Povorcitinib, developed by Incyte Corporation, is a selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules to treat patients with moderate-to-severe hidradenitis suppurativa. This therapeutic molecule is administered orally. Currently, the company is investigating this molecule in three different Phase III clinical trials (STOP-HS studies) for moderate-to-severe hidradenitis suppurativa. The company expects the Phase III STOP-HS trial data in 2025. In addition, the company also anticipates the potential launch of povorcitinib for hidradenitis suppurativa by 2026-2027.

* Sonelokimab (M1095): MoonLake Immunotherapeutics

Sonelokimab (M1095) is an investigational ~40 kDa humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. Nanobodies represent a new generation of antibody-derived targeted therapies. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers.

To know more about Hidradenitis Suppurativa treatment guidelines, visit @ Hidradenitis Suppurativa Treatment Market Landscape [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Hidradenitis Suppurativa Drugs Market Insights

Hidradenitis suppurativa is treated using a variety of therapeutic classes tailored to its severity. Topical treatments, including antibiotics and antiseptics, are often used for milder cases. Systemic therapies, such as oral antibiotics, hormonal treatments, and retinoids, are utilized for more extensive disease. Biologic therapies, particularly TNF-alpha inhibitors and interleukin inhibitors, are effective for moderate-to-severe hidradenitis suppurativa. Immunosuppressants like cyclosporine and methotrexate are also options. The diverse Hidradenitis Suppurativa pipeline includes treatments targeting interleukins (such as IL-17, IL-36, and IL-1a/b), PDE4 inhibitors, JAK inhibitors, and CXCR1 and CXCR2 inhibitors.

Hidradenitis Suppurativa Market Outlook

As there is no cure for hidradenitis suppurativa, early diagnosis, and treatment help prevent the disease from getting worse and forming additional scars, and the current treatment approaches depend on the severity and clinical staging of the disease. Regarding pharmacological treatment market options, the following therapies are available: topical and systemic antibiotics, corticosteroids, hormonal therapy, systemic retinoids, zinc supplements, and immunosuppressive agents, including biologics. The mainstay of medical treatment of mild disease involves antibacterial washes and topical antibiotics. Acute flares may be managed by intralesional corticosteroids and/or minor surgical procedures. Oral therapies for mild-to-moderate hidradenitis suppurativa include extended courses of broad-spectrum antibiotics and systemic retinoids. In off-label therapies, the commonly used antibiotics are clindamycin, rifampicin, and tetracycline, as these antibiotics have shown their efficacy in the studies.

Learn more about the FDA-approved drugs for Hidradenitis Suppurativa @ Drugs for Hidradenitis Suppurativa Treatment [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hidradenitis Suppurativa Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Hidradenitis Suppurativa Companies- Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics, Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, Aristea Therapeutics, and others.
* Hidradenitis Suppurativa Pipeline Therapies- IFX-1, Cosentyx /Secukinumab, Avacopan, Bimekizumab, Bermekimab, Zunsemetinib (ATI-450), and others.
* Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa Market Drivers and Barriers
* Hidradenitis Suppurativa Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Report Introduction

3. Hidradenitis Suppurativa Market Overview at a Glance: 7MM

4. Executive Summary of Hidradenitis Suppurativa

5. Key Events

6. Epidemiology and Market Methodology

7. Disease Overview: Hidradenitis Suppurativa

8. Treatment and Guidelines

9. Epidemiology and Patient Population

10. Patient Journey of Hidradenitis Suppurativa

11. Key Endpoints in Hidradenitis Suppurativa Clinical Trials

12. Marketed Drugs

13. Emerging Drugs

14. Hidradenitis Suppurativa: Market Analysis

15. Market Access and Reimbursement

16. Unmet Needs

17. SWOT Analysis

18. KOL Views

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hidradenitis-suppurativa-therapeutics-market-size-was-nearly-usd-1400-million-in-the-7mm-in-2023-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.